Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 2 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Di Trana A, Berardinelli D, Montanari E, Berretta P, Basile G, Huestis MA, Busard? FP. Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. Int J Mol Sci. 2022 Nov 23; 23(23).
-
Hanlon JT, Zhao X, Naples JG, Aspinall SL, Perera S, Nace DA, Castle NG, Greenspan SL, Thorpe CT. Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents. J Am Geriatr Soc. 2017 Jun; 65(6):1183-1189.
-
Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine Infusions for Treatment Refractory Headache. Headache. 2017 Feb; 57(2):276-282.
-
Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017 Jan; 57(1):165-178.
-
Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 05; 87(1):41-8.
-
Shayan G, Choi YS, Shusta EV, Shuler ML, Lee KH. Murine in vitro model of the blood-brain barrier for evaluating drug transport. Eur J Pharm Sci. 2011 Jan 18; 42(1-2):148-55.
-
Erve JC, Beyer CE, Manzino L, Talaat RE. Metabolite identification in rat brain microdialysates by direct infusion nanoelectrospray ionization after desalting on a ZipTip and LTQ/Orbitrap mass spectrometry. Rapid Commun Mass Spectrom. 2009 Dec; 23(24):4003-12.
-
Stefanacci RG, Cavallaro E, Beers MH, Fick DM. Developing explicit positive beers criteria for preferred central nervous system medications in older adults. Consult Pharm. 2009 Aug; 24(8):601-10.
-
Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009 Mar; 31(3):542-59.
-
Rossi MI, Young A, Maher R, Rodriguez KL, Appelt CJ, Perera S, Hajjar ER, Hanlon JT. Polypharmacy and health beliefs in older outpatients. Am J Geriatr Pharmacother. 2007 Dec; 5(4):317-23.